Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease
The gut microbiota can impact the bioavailability of therapeutic drugs. Here, the authors show that bacterial tyrosine decarboxylases (TDC) decrease the levels of levodopa, the primary treatment in Parkinson’s disease, by conversion to dopamine, and suggest TDC as a potential predictive biomarker fo...
Enregistré dans:
Auteurs principaux: | Sebastiaan P. van Kessel, Alexandra K. Frye, Ahmed O. El-Gendy, Maria Castejon, Ali Keshavarzian, Gertjan van Dijk, Sahar El Aidy |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2019
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/b417af8f89cb4dab815828a72e3ff5dd |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Protein intake and the use of levodopa in patients with Parkinson's disease
par: de Moraes Fracasso,Bianca, et autres
Publié: (2013) -
Correlation between Serum Zinc Levels and Levodopa in Parkinson’s Disease
par: Hirofumi Matsuyama, et autres
Publié: (2021) -
Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
par: Bargiotas P, et autres
Publié: (2013) -
Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
par: David J Brooks
Publié: (2008) -
Exome-wide association study of levodopa-induced dyskinesia in Parkinson’s disease
par: Eva König, et autres
Publié: (2021)